Kymera Therapeutics, Inc. Common Stock

Kymera's 15.11% short interest stands out as notably elevated, suggesting meaningful skepticism despite the company's $7.1B valuation. The stock trades below its 52-week high with a neutral RSI of 48, indicating neither overbought nor oversold conditions—a rare equilibrium. The absence of a P/E ratio signals ongoing losses, which paired with the substantial short position, implies the market is heavily debating whether the biotech's pipeline justifies its current valuation. This setup carries classic squeeze characteristics if clinical progress materializes, though the elevated short thesis also reflects legitimate profitability concerns that shorts are betting won't resolve near-term.